Morning Overview on MSNOpinion

Promising cancer blood test masks a critical weakness

Blood tests that promise to spot cancer before symptoms appear are racing toward clinics, pitched as a simple vial of blood ...
Fierce Biotech

FDA approves next-gen prostate cancer PSA test from Cleveland Diagnostics

The FDA has approved a novel diagnostic for prostate cancer that looks to improve upon the common screener for ...
Targeted Oncology

FDA Approves Novel Blood-Based Assay to Stratify Prostate Cancer Biopsy Risk

The FDA has granted premarket approval (PMA) to the IsoPSA test, a novel, blood-based in vitro diagnostic kit designed to ...
MedTech Dive

Cleveland Diagnostics wins FDA nod for prostate cancer test

The IsoPSA test is intended to help assess whether patients with elevated PSA levels should go on to receive a biopsy ...

Stage 4 prostate cancer cases increased after reduction in PSA screening, research suggests

New research suggests that cases of stage 4 prostate cancer have gone up since Canada changed guidelines for a screening ...
MedPage Today on MSN

FDA OKs Blood-Based Test to Help Detect High-Grade Prostate Tumors

The FDA approved Cleveland Diagnostics' blood-based test to help diagnose high-grade prostate tumors and aid in biopsy decisions, the company announced.

FDA Approves IsoPSA(R) -- Cleveland Diagnostics' Novel Blood-Based Prostate Cancer Test

IsoPSA Test Evaluates Prostate Cancer-Specific Structural Variants of the PSA Protein to Aid in the Diagnosis of High-Grade Prostate Cancer ...
360Dx

Cleveland Diagnostics Nabs FDA Approval for Prostate Cancer Test

The blood-based test is intended to aid in the decision for prostate biopsy for men older than 50 with elevated PSA levels.